<DOC>
	<DOC>NCT01678781</DOC>
	<brief_summary>A study to evaluate, by country and overall, the changes from baseline of the irritable bowel syndrome quality of life (IBS QoL) total score after 4 and 8 weeks of treatment with Duspatalin® or Dicetel® in IBS patients.</brief_summary>
	<brief_title>Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Mebeverine</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Pinaverium</mesh_term>
	<mesh_term>Alverine</mesh_term>
	<criteria>Irritable bowel syndrome patients diagnosed by Rome III criteria (18 years or older) Pregnancy and lactation Specific contraindications to mebeverine hydrochloride or pinaverium bromide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Abdominal pain</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Mebeverine hydrochloride</keyword>
	<keyword>Constipation</keyword>
	<keyword>Pinaverium bromide</keyword>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>Bloating</keyword>
	<keyword>Quality of life</keyword>
</DOC>